Genetic engineering of T cells for adoptive immunotherapy
- 8 October 2008
- journal article
- review article
- Published by Springer Nature in Immunologic Research
- Vol. 42 (1-3) , 166-181
- https://doi.org/10.1007/s12026-008-8057-6
Abstract
To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.Keywords
This publication has 90 references indexed in Scilit:
- Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorNature Medicine, 2008
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesNature Biotechnology, 2008
- Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleasesProceedings of the National Academy of Sciences, 2008
- Gene transfer in humans using a conditionally replicating lentiviral vectorProceedings of the National Academy of Sciences, 2006
- CD8+ T‐cell memory in tumor immunology and immunotherapyImmunological Reviews, 2006
- Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide‐MHC without increasing apparent cross‐reactivityProtein Science, 2006
- Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vectorNature Biotechnology, 2004
- The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeysNature, 2004
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999